• Mednow (MNOW) reported Q1/23 revenue increased approximately 35 per cent Q/Q to $9.7 million, and approximately 1,300 per cent year-over-year
  • Mednow patient count by approximately 13 per cent to ~35,000 in Q1’23 versus ~31,000 in Q4’22
  • Reduced costs by 30 per cent, achieved additional cost savings post-Q1’23 to further reduce cash burn
  • Ali Reyhany, Founder & CEO of Mednow, sat down with Sabrina Cuthbert to discuss the results
  • Mednow is a healthcare technology company
  • Mednow Inc. (MNOW) opened trading at $0.29 per share

Mednow (MNOW) has released its financial results for the period ending October 31, 2022 (Q1 2023).

In fiscal Q1, revenue increased by approximately 35 per cent Q/Q to $9.7 million, and approximately 1,300 per cent year-over-year

Mednow’s patient count increased by approximately 13 per cent to ~35,000 in Q1’23 versus ~31,000 in Q4’22.

Ali Reyhany, Founder & CEO of Mednow, sat down with Sabrina Cuthbert to discuss the results.

Mednow is a Canadian-based healthcare technology company. Mednow.ca provides virtual pharmacy and telemedicine services, as well as doctor home visits.

Mednow Inc. (MNOW) opened trading at $0.29 per share. 


More From The Market Online

Canada’s hidden growth engines: Why 2025 is the year to bet on small-cap stocks

Small-cap stocks in Canada have lagged behind large caps, weighed down by volatility, limited analyst coverage, and investor caution.

Cyber safety guide reveals alarming surge in cyberattacks on U.S. healthcare sector

CyberCatch Holdings (TSXV:CYBE) released its Health Industry Cyber Safety Guide to help healthcare organizations combat cyberattacks.

Sona Nanotech doses first patient in groundbreaking cancer therapy trial

Sona Nanotech (CSE:SONA), a life sciences company, has announced a major milestone in the development of its novel cancer treatment.

Cancer diagnosis? Here is a lifeline to a second opinion

Sun Life US announced the launch of its new Expert Cancer Review service, designed to support members facing...